Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. More Details
+ 2 more risks
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Exopharm's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EX1 is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: EX1's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
7 Day Return
1 Year Return
Return vs Industry: EX1 exceeded the Australian Biotechs industry which returned -8.3% over the past year.
Return vs Market: EX1 exceeded the Australian Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Exopharm's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
2 months ago | Simply Wall StShareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 188%
11 months ago | Simply Wall StIs Exopharm (ASX:EX1) In A Good Position To Invest In Growth?
Is Exopharm undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EX1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EX1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EX1 is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.
PE vs Market: EX1 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EX1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EX1 is overvalued based on its PB Ratio (9.4x) compared to the AU Biotechs industry average (4.9x).
How is Exopharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Exopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Exopharm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EX1 is currently unprofitable.
Growing Profit Margin: EX1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EX1 is unprofitable, and losses have increased over the past 5 years at a rate of 49.1% per year.
Accelerating Growth: Unable to compare EX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EX1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).
Return on Equity
High ROE: EX1 has a negative Return on Equity (-77.58%), as it is currently unprofitable.
How is Exopharm's financial position?
Financial Position Analysis
Short Term Liabilities: EX1's short term assets (A$8.4M) exceed its short term liabilities (A$1.6M).
Long Term Liabilities: EX1's short term assets (A$8.4M) exceed its long term liabilities (A$323.4K).
Debt to Equity History and Analysis
Debt Level: EX1 is debt free.
Reducing Debt: EX1 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EX1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EX1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 42.6% each year
What is Exopharm current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EX1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EX1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EX1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EX1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EX1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Ian E. Dixon, PhD, MBA, MAICD, is Company Founder and Technology Co-Founder of Exopharm Limited and has been its Managing Director and Director since 2020. Dr. Dixon serves as Non-Executive Director at...
CEO Compensation Analysis
Compensation vs Market: Ian's total compensation ($USD200.11K) is below average for companies of similar size in the Australian market ($USD287.84K).
Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.
Experienced Management: EX1's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46%.
Exopharm Limited's company bio, employee growth, exchange listings and data sources
- Name: Exopharm Limited
- Ticker: EX1
- Exchange: ASX
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$90.619m
- Shares outstanding: 139.41m
- Website: https://www.exopharm.com
Number of Employees
- Exopharm Limited
- 31 Queen Street
- Level 17
Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Naïve EVs...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/08 08:16|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.